Myriad Genetics (MYGN) Competitors $15.49 +0.37 (+2.45%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MYGN vs. NTLA, HSKA, VIVO, QDEL, IONS, ALKS, FOLD, GERN, LGND, and MNKDShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Intellia Therapeutics (NTLA), Heska (HSKA), Meridian Bioscience (VIVO), QuidelOrtho (QDEL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), Ligand Pharmaceuticals (LGND), and MannKind (MNKD). These companies are all part of the "medical" sector. Myriad Genetics vs. Intellia Therapeutics Heska Meridian Bioscience QuidelOrtho Ionis Pharmaceuticals Alkermes Amicus Therapeutics Geron Ligand Pharmaceuticals MannKind Myriad Genetics (NASDAQ:MYGN) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Is MYGN or NTLA more profitable? Intellia Therapeutics has a net margin of 0.00% compared to Myriad Genetics' net margin of -14.09%. Myriad Genetics' return on equity of -4.51% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Myriad Genetics-14.09% -4.51% -3.07% Intellia Therapeutics N/A -49.34%-40.27% Do analysts rate MYGN or NTLA? Myriad Genetics currently has a consensus price target of $27.36, suggesting a potential upside of 76.65%. Intellia Therapeutics has a consensus price target of $54.94, suggesting a potential upside of 284.18%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Myriad Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Myriad Genetics 2 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.42Intellia Therapeutics 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.72 Which has more volatility & risk, MYGN or NTLA? Myriad Genetics has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Do insiders and institutionals believe in MYGN or NTLA? 99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 2.1% of Myriad Genetics shares are held by company insiders. Comparatively, 3.2% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor MYGN or NTLA? Myriad Genetics received 34 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. However, 69.27% of users gave Intellia Therapeutics an outperform vote while only 53.23% of users gave Myriad Genetics an outperform vote. CompanyUnderperformOutperformMyriad GeneticsOutperform Votes46953.23% Underperform Votes41246.77% Intellia TherapeuticsOutperform Votes43569.27% Underperform Votes19330.73% Does the media prefer MYGN or NTLA? In the previous week, Intellia Therapeutics had 14 more articles in the media than Myriad Genetics. MarketBeat recorded 27 mentions for Intellia Therapeutics and 13 mentions for Myriad Genetics. Intellia Therapeutics' average media sentiment score of 0.39 beat Myriad Genetics' score of 0.21 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 6 Very Positive mention(s) 7 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, MYGN or NTLA? Myriad Genetics has higher revenue and earnings than Intellia Therapeutics. Myriad Genetics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyriad Genetics$753.20M1.87-$263.30M-$1.30-11.92Intellia Therapeutics$43.09M33.80-$481.19M-$5.44-2.63 SummaryIntellia Therapeutics beats Myriad Genetics on 11 of the 19 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41B$2.28B$5.38B$8.84BDividend YieldN/A0.75%5.13%4.09%P/E Ratio-11.926.14105.1417.83Price / Sales1.8743.531,233.15158.41Price / CashN/A14.8240.4136.29Price / Book1.933.137.096.50Net Income-$263.30M$29.98M$119.65M$226.22M7 Day Performance1.57%4.76%2.25%4.03%1 Month Performance-30.60%-9.17%-2.33%4.92%1 Year Performance-12.49%-13.97%33.98%29.30% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics4.2883 of 5 stars$15.49+2.4%$27.36+76.7%-12.5%$1.41B$753.20M-11.922,700Analyst DowngradeNTLAIntellia Therapeutics4.5493 of 5 stars$13.86+5.6%$54.94+296.3%-52.7%$1.41B$36.28M-2.58600Analyst ForecastAnalyst RevisionHSKAHeskaN/A$119.99flatN/AN/A$1.31B$257.31M-62.17808VIVOMeridian Bioscience1.0401 of 5 stars$33.97flatN/AN/A$1.50B$333.02M35.02702QDELQuidelOrtho4.6164 of 5 stars$37.89+1.1%$58.83+55.3%-41.8%$2.55B$3.00B-1.347,100Analyst ForecastInsider TradeIONSIonis Pharmaceuticals4.087 of 5 stars$33.83-4.4%$60.65+79.3%-31.4%$5.34B$788M-13.86800ALKSAlkermes4.5585 of 5 stars$27.79-0.4%$35.42+27.4%+18.0%$4.50B$1.66B14.312,100Positive NewsFOLDAmicus Therapeutics4.5635 of 5 stars$9.50-0.9%$17.63+85.5%-9.2%$2.84B$399.36M-27.94480GERNGeron3.5551 of 5 stars$4.02+0.8%$7.05+75.4%+108.7%$2.43B$240,000.00-12.56141LGNDLigand Pharmaceuticals4.9274 of 5 stars$116.86+4.8%$144.83+23.9%+100.3%$2.21B$131.31M46.5680Positive NewsMNKDMannKind3.7548 of 5 stars$6.90+0.3%$8.67+25.6%+87.4%$1.90B$198.96M98.61400Analyst DowngradeInsider Trade Related Companies and Tools Related Companies NTLA Alternatives HSKA Alternatives VIVO Alternatives QDEL Alternatives IONS Alternatives ALKS Alternatives FOLD Alternatives GERN Alternatives LGND Alternatives MNKD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYGN) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
